Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nefazodone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A known ✓ | P28223 | 5/20 | 0.97 |
| ▸ | SLC6A4 known ✓ | P31645 | 4/20 | 0.97 |
| ▸ | SLC6A2 known ✓ | P23975 | 4/20 | 0.97 |
| ▸ | HTR2C known ✓ | P28335 | 3/20 | 0.97 |
| ▸ | DRD2 | P14416 | 6/20 | 0.97 |
| ▸ | DRD3 | P35462 | 5/20 | 0.97 |
| ▸ | HTR1A | P08908 | 5/20 | 0.97 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.97 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.97 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.97 |
| ▸ | DRD1 | P21728 | 3/20 | 0.97 |
| ▸ | DRD4 | P21917 | 3/20 | 0.97 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.97 |
| ▸ | HRH1 | P35367 | 3/20 | 0.97 |
| ▸ | HTR7 | P34969 | 3/20 | 0.97 |
| ▸ | HTR6 | P50406 | 3/20 | 0.97 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.97 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.97 |
| ▸ | MEN1 | O00255 | 2/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nefazodone SCHEMBL35089 | 0.98 | DRD2 (1.00) | DRD2HTR2ADRD3HTR1ASLC6A4 | |
| Nefazodone SCHEMBL29375893 | 0.98 | DRD2 (1.00) | DRD2HTR2ADRD3HTR1ASLC6A4 | |
| Nefazodone SCHEMBL6479060 | 0.98 | DRD2 (1.00) | DRD2HTR2ADRD3HTR1ASLC6A4 | |
| Nefazodone SCHEMBL41119 | 0.97 | DRD2 (1.00) | DRD2HTR2ADRD3HTR1ASLC6A4 | |
| Nefazodone SCHEMBL30054492 | 0.97 | DRD2 (1.00) | DRD2HTR2ADRD3HTR1ASLC6A4 | |
| Nefazodone SCHEMBL8195097 | 0.97 | DRD2 (1.00) | DRD2HTR2ADRD3HTR1ASLC6A4 | |
| Nefazodone SCHEMBL9275261 | 0.97 | DRD2 (0.98) | DRD2HTR2ADRD3HTR1ASLC6A4 | |
| Nefazodone SCHEMBL5501519 | 0.97 | DRD2 (1.00) | DRD2HTR2ADRD3HTR1ASLC6A4 | |
| Nefazodone SCHEMBL27748020 | 0.97 | DRD2 (0.98) | DRD2HTR2ADRD3HTR1ASLC6A4 | |
| Nefazodone SCHEMBL27748022 | 0.97 | DRD2 (0.98) | DRD2HTR2ADRD3HTR1ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1580 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250241910-A1 | COMBINATION THERAPY FOR THE TREATMENT OF PSYCHIATRIC DISORDER | GSKB Pharmaceuticals, LLC | 2025-07-31 | — | — | US | claimed |
| US-20240350483-A1 | COMBINATION THERAPY FOR THE TREATMENT OF PSYCHIATRIC DISORDER | GSKB Pharmaceuticals, LLC | 2024-10-24 | — | — | US | claimed |
| US-12102653-B2 | Ligand regulated protein-protein interaction system | ST. ANNA KINDERKREBSFORSCHUNG (AT) | 2024-10-01 | — | — | US | claimed |
| CN-118206634-A | Ligand-regulated protein-protein interaction system | 圣安娜儿童癌症研究中心 | 2024-06-18 | — | — | CN | claimed |
| CN-118196515-A | Zebra fish phenotype identification method | 福建医科大学附属第一医院 | 2024-06-14 | — | — | CN | claimed |
| US-20240000841-A1 | LIGAND REGULATED PROTEIN-PROTEIN INTERACTION SYSTEM | ST ANNA KINDERKREBSFORSCHUNG (AT) | 2024-01-04 | — | — | US | claimed |
| US-11844813-B2 | Ligand regulated protein-protein interaction system | ST. ANNA KINDERKREBSFORSCHUNG (AT) | 2023-12-19 | — | — | US | claimed |
| US-20230003721-A1 | MITOTHERAPEUTICS FOR THE TREATMENT OF BRAIN DISORDERS | THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2023-01-05 | — | — | US | claimed |
| CN-111405895-B | Controlled release pharmaceutical composition and preparation method thereof | 江苏恒瑞医药股份有限公司 | 2022-10-21 | — | — | CN | claimed |
| US-11344496-B2 | Methods for preparing stabilized amorphous drug formulations using acoustic fusion | MERCK SHARP & DOHME CORP. (US) | 2022-05-31 | — | — | US | claimed |
| WO-2000025790-A1 | CONTROLLED DELIVERY OF ANTIDEPRESSANTS | ALZA CORPORATION (US) | 2000-05-11 | — | — | WO | claimed |
| EP-0966966-A2 | Nefazodone dosage form | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-12-29 | — | — | EP | claimed |
| CN-1238181-A | Nefazodone dosage form | BRISTOL MYERS SQUIBB CO (US) | 1999-12-15 | — | — | CN | claimed |
| EP-0946096-A4 | NEFAZODONE: USE IN TREATING POST TRAUMATIC STRESS DISORDER | BRISTOL MYERS SQUIBB CO (US) | 1999-11-24 | — | — | EP | claimed |
| EP-0946096-A1 | NEFAZODONE: USE IN TREATING POST TRAUMATIC STRESS DISORDER | Bristol-Myers Squibb Company (US) | 1999-10-06 | — | — | EP | claimed |
| US-5854248-A | Nefazodone: use in migraine prophylaxis | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-12-29 | — | — | US | claimed |
| US-5852020-A | Nefazodone: use in treating post traumatic stress disorder | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-12-22 | — | — | US | claimed |
| WO-1998021958-A1 | NEFAZODONE: USE IN TREATING POST TRAUMATIC STRESS DISORDER | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-05-28 | — | — | WO | claimed |
| WO-1998004261-A1 | NEFAZODONE: USE IN MIGRAINE PROPHYLAXIS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-02-05 | — | — | WO | claimed |
| EP-0769297-A1 | Use of nefazodone for the manufacture of a medicament for the treatment of panic attack | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-04-23 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240350483-A1 | COMBINATION THERAPY FOR THE TREATMENT OF PSYCHIATRIC DISORDER | SLC6A4, SLC6A2, SLC6A3 | HTR2A 47/4885SLC6A4 1/4885SLC6A2 2/4885 |
| US-11344496-B2 | Methods for preparing stabilized amorphous drug formulations using acoustic fusion | PDE8B, RPS27A, PDE8A | HTR2A 4310/4885SLC6A4 2182/4885SLC6A2 1884/4885 |
| US-20250241910-A1 | COMBINATION THERAPY FOR THE TREATMENT OF PSYCHIATRIC DISORDER | SLC6A4, SLC6A2, SLC6A3 | HTR2A 47/4885SLC6A4 1/4885SLC6A2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.